AstraZeneca’s lung cancer drug Tagrisso looks set to gain further traction after the FDA approved it in first-line treatment for lung cancer patients with a certain mutation. The approval, for untreated patients with metastatic non-small cell lung...
Original Article: AZ's Tagrisso approved for untreated lung cancer in US